Prostate Cancer Drugs Could Pose Risk to Heart Health

FDA reviewing safety of anti-hormone treatments due to links with heart disease and diabetes.

The Food and Drug Administration (FDA) has announced that it is investigating the safety of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs used to treat prostate cancer, after evidence linking them with a rise in the risk of heart disease and diabetes. Its not the first time concerns have been raised about the use of hormone therapy to treat prostate cancer-a 2009 study suggested it raises the risk of heart disease by as much as 25 percent
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access